新型抗骨质疏松药物romosozumab

A new antiosteoporosis drug:romosozumab

romosozumab(EVENITY^TM,romosozumab-aqqg)是一种人源化骨硬化蛋白的单克隆抗体,于2019年4月9日经FDA批准上市,用于骨质疏松症的治疗,尤其适用于高骨折风险的绝经女性患者。目前多项临床试验证实该药能显著增加受试者的骨密度,降低脆性骨折的风险。本文从作用机制、药效学、药动学、临床试验、安全性及用法用量对该药进行综述,以期为今后的临床应用提供参考。

Romosozumab(EVENITY^TM),a humanized monoclonal antibody against sclerostin,was approved by the U.S.FDA on April 9 th,2019 for the treatment of osteoporosis in postmenopausal women at high risk.Now many clinical trials have shown that the drug significantly increases bone mineral density and reduces the risk of fragile fractures.In this paper,the mechanism of action,pharmacodynamics,pharmacokinetics,clinical trials,safety,dosage and administration of the drug were reviewed in order to provide reference for its future clinical application.